Bio-Rad Launches ddSEQ Single-Cell 3' RNA-Seq Kit for Single-Cell Gene Expression
Bio-Rad Laboratories, Inc. recently announced the launch of the ddSEQ Single-Cell 3′ RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research.
Designed to be run on Bio-Rad’s droplet-based single-cell isolation system, the ddSEQ Cell Isolator, the ddSEQ Single-Cell 3′ RNA-Seq Kit delivers high-quality single-cell 3′ RNA-Seq libraries in a fast, efficient, and affordable workflow, allowing researchers to easily conduct single-cell gene expression and regulation analyses. The subsequent QC, analysis, and reporting of data generated from the ddSEQ Single-Cell 3′ RNA-Seq Kit is enabled by the accompanying Omnition v1.1 Analysis Software, a robust pipeline analysis tool. These valuable insights into single-cell transcription and gene expression support a broad range of research fields such as oncology, immunology, neurology, and stem cell biology.
“The new ddSEQ Single-Cell 3′ RNA-Seq Kit expands our NGS library preparation portfolio and is a further reflection of our commitment to provide researchers with innovative technologies to support molecular biology, oncology, and drug discovery research,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Used with our ddSEQ Cell Isolator, the new kit and Omnition v1.1 Analysis Software presents a more cost-effective solution for single-cell transcription and gene expression studies, facilitating seamless integration into a broad spectrum of research applications and empowering research teams to undertake more experiments within the same budget.”
To learn more about the ddSEQ Single-Cell 3′ RNA-Seq Kit, visit www.bio-rad.com/ddSEQ3scRNA-SeqKit
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, CA, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. For more information, visit bio-rad.com.
Total Page Views: 412
